D. Dearnaley

Publications673
h-index91
Citations33,949
Highly Influential Citations1,076
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • C. Parker
  • 476 Publications • 31,171 Citations
  • A. Horwich
  • 507 Publications • 31,350 Citations
  • M. Sydes
  • 347 Publications • 22,862 Citations
  • R. Huddart
  • 598 Publications • 22,531 Citations
  • Publications
  • Influence
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised…
View on Elsevier
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
TLDR
Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
View on Wolters Kluwer
Multiple newly identified loci associated with prostate cancer susceptibility
TLDR
A genome-wide association study using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at ≤60 years or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (<0.5 ng/ml) identified seven loci associated with prostate cancer on chromosomes 3, 6, 7, 10, 11, 19 and X.
View on Nature
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
TLDR
CYP17 blockade by abiraterone acetate is safe and has significant antitumor activity in CRPC, and data confirm that CRPC commonly remains dependent on ligand-activated AR signaling.
View on PubMed
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
TLDR
A significant association between ERG rearrangements in therapy-naive tumors, CRPCs, and CTCs and magnitude of prostate-specific antigen decline is reported and indicates that hormone-regulated expression of ERG persists in CRPC.
View on PubMed
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
View on PubMed
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
TLDR
YP17 blockade by abiraterone acetate results in declines in PSA and CTC counts and radiologic responses, confirming that CRPC commonly remains hormone driven.
View on PubMed
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical…
View on PubMed
Multiple loci with different cancer specificities within the 8q24 gene desert.
TLDR
It is concluded that there are at least five separate functional variants in this region that are associated with the risk of prostate, colorectal, and ovarian cancer, but not breast cancer.
View on PubMed
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
View on PubMed
...
...